Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

0.1887

-0.0021

(-1.10%)

At close: 03:59PM EDT

0.1905

+0.00

(+0.95%)

After hours:

07:56PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	0.1908
Open	0.1919
Bid	0.1876 x 900
Ask	0.1905 x 1400
Day's Range	0.1857 - 0.1956
52 Week Range	0.1600 - 0.9800
Volume	281,991
Avg. Volume	593,337

Market Cap	23.102M
Beta (5Y Monthly)	1.99
PE Ratio (TTM)	N/A
EPS (TTM)	-0.0680
Earnings Date	Mar 23, 2022 - Mar 28, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	1.50

All

GlobeNewswire
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all items of business, other than the proposed consolidation of the Company's shares (the "Share Consolidation"), were approved at its annual meetin
- FREEMAN GOLD ANNOUNCES RESULTS OF SHAREHOLDER MEETING AND AWARDS OF RESTRICTED SHARE UNITS
  CNW Group
- Universal Display Corporation Holds Virtual 2022 Annual Meeting of Shareholders
  Business Wire
GlobeNewswire
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program
– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th International Congress on Autoimmunity being held in Athens, Greece – Preliminary data with mouse 2D2 models of spontaneous autoimmune encephalomyelitis (EAE) indicate that mouse-adapted AIM Biologicals may reduce optic neuritis, loss of inner nuclear layer neurons and EAE symptoms TORONTO, ONTARIO, June
GlobeNewswire
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 12:3